 - Primary study: Patients make an initial visit before beginning doxorubicin hydrochloride treatment and a visit 3 weeks after the 4th course of doxorubicin hydrochloride approximately 12 weeks after the initial visit. During these visits, blood samples are also collected for measuring serum levels of neuregulin-1, IGF-1, cardiotropin-1, IL-6, VEGF, hepatocyte growth factor, and plasma norepinephrine and endothelial progenitor cells EPC. Heart-rate variability HRV is measured and, if necessary, a transthoracic echocardiogram is performed. Patients complete baseline health and activity level questionnaire and suitable patients complete a 6-minute walk test. Patients undergo blood collection for genotype analysis for single nucleotide polymorphism sites during the initial visit. 